Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Anemia

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    873 result(s) found for: Anemia. Displaying page 16 of 44.
    «« First « Previous 12  13  14  15  16  17  18  19  20  Next» Last»»
    EudraCT Number: 2004-004401-26 Sponsor Protocol Number: CT-830-04-0004 Start Date*: 2005-03-21
    Sponsor Name:STADA R&D GmbH
    Full Title: Evaluation of the Safety of a Formulation Containing Epoetin (Epoetin STADA) Administered Intravenously for the Maintenance Treatment of Renal Anemia: an Open Follow-up Trial. Study code (CRO) 411-...
    Medical condition: Anemia caused by terminal renal insufficiency
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-012746-23 Sponsor Protocol Number: JS001 Start Date*: 2009-05-12
    Sponsor Name:ISTITUTO GIANNINA GASLINI
    Full Title: pilot study of second line therapy for AAA Acquired Aplastic Anemia with antithymocyte globulin, cyclosporin and etanercept
    Medical condition: acquired aplastic anemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10005329 SOC
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-001720-13 Sponsor Protocol Number: ML20937 Start Date*: 2007-09-28
    Sponsor Name:Roche Nederland B.V.
    Full Title: A single arm, open label study to assess the efficacy, safety and tolerability of once-monthly administration of subcutaneous RO0503821 for the maintenance of haemoglobine levels in patients with c...
    Medical condition: chronic renal anemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10058116 Nephrogenic anaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-006523-40 Sponsor Protocol Number: ML20944 Start Date*: 2007-04-13
    Sponsor Name:Roche AB
    Full Title: A single arm open label study to assess the efficacy, safety and tolerability and of once-monthly administration of subcutaneous C.E.R.A. for the maintenance of haemoglobin levels in pre-dialysis p...
    Medical condition: Chronic renal anemia
    Disease: Version SOC Term Classification Code Term Level
    8.1 10058116 Nephrogenic anaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2007-005528-34 Sponsor Protocol Number: ML21348 Start Date*: 2008-02-22
    Sponsor Name:N.V. Roche S.A.
    Full Title: Subcutaneous Treatment of Anemia in patients with a GFR Below 45 ml/min/1.73m2 through Injections with Mircera as low frequent as Once monthly
    Medical condition: Chronic renal anaemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10058116 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2006-005621-28 Sponsor Protocol Number: ML20752 Start Date*: 2008-02-22
    Sponsor Name:Roche (Hungary) Ltd
    Full Title: A single arm, open label study to assess the efficacy, safety and tolerability of once-monthly administration of intravenous C.E.R.A. for the maintenance of haemoglobin levels in dialysis patients ...
    Medical condition: To assess the long term maintenance of haemoglobin levels, with once-monthly intravenous administration of C.E.R.A. in dialysis patients with chronic renal anaemia.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10058132 Renal anemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2022-001253-23 Sponsor Protocol Number: 4202-ONC-203 Start Date*: 2022-09-23
    Sponsor Name:Forma Therapeutics, Inc.
    Full Title: A Phase 2 Open-Label Study to Evaluate Etavopivat for the Treatment of Anemia in Patients with Myelodysplastic Syndromes (MDS)
    Medical condition: Anemia of myelodysplastic syndromes (MDS), inherited hemolytic anemias, and other refractory anemias
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004958-42 Sponsor Protocol Number: MOM-M281-003 Start Date*: 2019-01-11
    Sponsor Name:Momenta Pharmaceuticals, Inc.
    Full Title: A Multicenter, Open-Label Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Pregnant Women at High Risk for Early Onset Severe Hemolytic Disease ...
    Medical condition: Early onset Severe Hemolytic Disease of the fetus and newborn (HDFN)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10019512 Hemolytic disease due to Rh isoimmunization of fetus or newborn LLT
    Population Age: In utero, Under 18, Adults Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) NL (Completed) SE (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-001190-24 Sponsor Protocol Number: BAY85-3934/15653 Start Date*: 2013-11-12
    Sponsor Name:Bayer AG
    Full Title: A controlled, parallel group, open-label, multicenter extension study to investigate efficacy and safety of oral BAY 85-3934 and darbepoetin alfa comparator in the long term treatment of anemia in ...
    Medical condition: Anaemia of Chronic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004851 10058123 Renal anaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) IT (Completed) HU (Completed) ES (Completed) BG (Prematurely Ended) PL (Completed)
    Trial results: View results
    EudraCT Number: 2020-000607-36 Sponsor Protocol Number: ACE-536-MF-002 Start Date*: 2021-06-01
    Sponsor Name:Celgene Corporation
    Full Title: A PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF LUSPATERCEPT (ACE-536) VERSUS PLACEBO IN SUBJECTS WITH MYELOPROLIFERATIVE NEOPLASM-ASSOCIATED MYELOFIBROSIS ON CONCOM...
    Medical condition: Anemia associated with myeloproliferative neoplasm (MPN)-associated myelofibrosis (MF)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077161 Primary myelofibrosis PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10074689 Post polycythemia vera myelofibrosis LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10074690 Post essential thrombocythemia myelofibrosis LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10074692 Post essential thrombocythaemia myelofibrosis LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10074691 Post polycythaemia vera myelofibrosis LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028537 Myelofibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) CZ (Trial now transitioned) AT (Trial now transitioned) IE (Trial now transitioned) GR (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) HU (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-001773-17 Sponsor Protocol Number: FGCL-4592-082 Start Date*: 2017-11-06
    Sponsor Name:FibroGen, Inc.
    Full Title: A Phase 3 Randomized Double-Blind Placebo-Controlled Study Investigating the Efficacy and Safety of Roxadustat (FG-4592) for Treatment of Anemia in Patients with Lower Risk Myelodysplastic Syndrome...
    Medical condition: Anemia due to Myelodysplastic Syndrome (MDS) in International Prognostic Scoring System – Revised Very Low, Low, or Intermediate Risk with <5% Blasts, and has low red blood cell transfusion burden ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Ongoing) GB (GB - no longer in EU/EEA) BE (Completed) DK (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-004446-29 Sponsor Protocol Number: LIBERAL-Trial Start Date*: 2017-10-30
    Sponsor Name:University Hospital Wuerzburg, Institution under public law, represented by the Medical Director
    Full Title: Liberal transfusion strategy to prevent mortality and anaemia-associated, ischaemic events in elderly non-cardiac surgical patients
    Medical condition: Elderly patients (>= 70 years) undergoing intermediate- or high-risk non-cardiac surgery
    Disease: Version SOC Term Classification Code Term Level
    27.0 10022117 - Injury, poisoning and procedural complications 10048861 Anaemia postoperative PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-000770-19 Sponsor Protocol Number: D5740C00001 Start Date*: 2015-01-16
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Roxadustat for the Treatment of Anemia in Chronic Kidney Disease Patients not on D...
    Medical condition: Anemia in chronic kidney disease patients without dialysis.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004857 10076412 Chronic kidney disease stage 5 LLT
    20.0 100000004857 10076410 Chronic kidney disease stage 3 LLT
    20.0 100000004857 10076411 Chronic kidney disease stage 4 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) SK (Completed) HU (Completed) DE (Completed) ES (Completed) BG (Completed) PL (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2009-011513-24 Sponsor Protocol Number: CC-5013-MDS-005 Start Date*: 2009-12-14
    Sponsor Name:Celgene Corporation
    Full Title: A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO COMPARE THE EFFICACY AND SAFETY OF LENALIDOMIDE (REVLIMID®) VERSUS PLACEBO IN SUBJECTS WITH TRANSFUSION...
    Medical condition: TRANSFUSION-DEPENDENT ANEMIA DUE TO IPSS LOW OR INTERMEDIATE-1 RISK MYELODYSPLASTIC SYNDROMES WITHOUT DELETION 5Q [31] AND UNRESPONSIVE OR REFRACTORY TO ERYTHROPOIESIS-STIMULATING AGENT
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10068361 MDS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) DE (Completed) FR (Completed) CZ (Completed) AT (Completed) IT (Completed) PT (Completed) GB (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2004-002032-26 Sponsor Protocol Number: BH 18387 Start Date*: 2004-12-23
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: An open-label, multi-center study to document the efficacy, safety and tolerability of long-term administration of RO0503821 in patients with chronic renal anemia
    Medical condition: Patient with chronic renal anaemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) FI (Completed) HU (Completed) DK (Completed) SE (Completed) CZ (Completed) NO (Completed) IT (Completed) DE (Completed) AT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-003173-40 Sponsor Protocol Number: ML21439 Start Date*: 2008-07-01
    Sponsor Name:ROCHE
    Full Title: A single arm, open label study to assess the efficacy, safety and tolerability of once-monthly administration of subcutaneous C.E.R.A. for the maintenance of haemoglobin levels in pre-dialysis pati...
    Medical condition: Chronic renal anaemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10058123 Renal anaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-003695-36 Sponsor Protocol Number: Start Date*: 2012-09-07
    Sponsor Name:Brighton & Sussex University Hospitals NHS Trust
    Full Title: Is intravenous iron and darbepoetin more effective than oral iron in reducing blood transfusion requirements for patients undergoing cardiac surgery
    Medical condition: Anaemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10005329 - Blood and lymphatic system disorders 10066761 Acute anaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-002268-42 Sponsor Protocol Number: 205767 Start Date*: 2018-03-29
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A randomized, repeat dose, open label, parallel group, multi-center study to evaluate the effect of daprodustat compared to darbepoetin alfa on forearm blood flow in participants with anemia of chr...
    Medical condition: anemia associated with chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-003986-20 Sponsor Protocol Number: LUCAS Start Date*: 2021-09-06
    Sponsor Name:Leipzig University
    Full Title: A Phase II, Open-Label, Multicenter Study of Orally Administered CA-4948 for the Treatment of Anemia in Patients with Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS)
    Medical condition: Anemia in patients with very low, low or intermediate risk myelodysplastic syndromes (MDS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028533 Myelodysplastic syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004029-21 Sponsor Protocol Number: INCB00928-104 Start Date*: 2021-01-08
    Sponsor Name:Incyte Corporation
    Full Title: A Phase 1/2 Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders
    Medical condition: Anaemia associated with myelofibrosis whether as a de novo disorder (PMF) or evolve secondarily from previous PV or ET (post–PV MF or post–ET MF).
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028537 Myelofibrosis PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10074689 Post polycythemia vera myelofibrosis LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10074690 Post essential thrombocythemia myelofibrosis LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10074691 Post polycythaemia vera myelofibrosis LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10074692 Post essential thrombocythaemia myelofibrosis LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077161 Primary myelofibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 12  13  14  15  16  17  18  19  20  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 01 23:50:19 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA